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Abstract
Background: Cigarette smoke, the major risk factor for COPD, is known to activate matrix metalloproteinases in
airway epithelium. We investigated whether metalloproteinases, particularly A Disintegrin and Metalloproteinase
(ADAM)17, contribute to increased pro-inflammatory epithelial responses with respect to the release of IL-8 and
TGF-a, cytokines implicated in COPD pathogenesis.
Methods: We studied the effects of cigarette smoke extract (CSE) and metalloproteinase inhibitors on TGF-a and
IL-8 release in primary bronchial epithelial cells (PBECs) from COPD patients, healthy smokers and non-smokers.
Results: We observed that TGF-a was mainly shed by ADAM17 in PBECs from all groups. Interestingly, IL-8
production occurred independently from ADAM17 and TGF-a shedding, but was significantly inhibited by broad-
spectrum metalloproteinase inhibitor TAPI-2. CSE did not induce ADAM17-dependent TGF-a shedding, while it
slightly augmented the production of IL-8. This was accompanied by reduced endogenous inhibitor of
metalloproteinase (TIMP)-3 levels, suggesting that CSE does not directly but rather indirectly alter activity of
ADAM17 through the regulation of its endogenous inhibitor. Furthermore, whereas baseline TGF-a shedding was
lower in COPD PBECs, the early release of IL-8 (likely due to its shedding) was higher in PBECs from COPD than
healthy smokers. Importantly, this was accompanied by lower TIMP-2 levels in COPD PBECs, while baseline TIMP-3
levels were similar between groups.
Conclusions: Our data indicate that IL-8 secretion is regulated independently from ADAM17 activity and TGF-a
shedding and that particularly its early release is differentially regulated in PBECs from COPD and healthy smokers.
Since TIMP-2-sensitive metalloproteinases could potentially contribute to IL-8 release, these may be interesting
targets to further investigate novel therapeutic strategies in COPD.
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Introduction
C h r o n i cO b s t r u c t i v eP u l m o n a r yD i s e a s e( C O P D )i s
characterized by ongoing airway inflammation, which is
associated with pulmonary emphysema and/or airway
remodeling. This results in airway obstruction and
accelerated lung function decline. Although smoking is
the major cause of COPD, it is still unclear how
different phenotypes of COPD develop from the same
exposure to cigarette smoke. When inhaled, cigarette
s m o k ef i r s te n c o u n t e r st h ea i r w a ye p i t h e l i u mt h a tc o n -
stitutes a barrier to environmental substances. Aberrant
repair to smoke-induced injury may lead to remodeling
of airway epithelium, an important feature of COPD
that includes squamous metaplasia and mucous cell
hypertrophy. This may reduce epithelial barrier function
in association with increased pro-inflammatory epithelial
activity.
Matrix metalloproteinase (MMP)s and A Disintegrin
and Metalloproteinase (ADAM)s are thought to play an
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tory diseases, including COPD [1]. The disintegrin
domain of ADAMs is involved in regulation of integrin-
mediated cell adhesion, while the metalloproteinase
domain can induce surface cleavage of heparan sulfate
proteoglycans (HSPG), growth factors, cytokines, extra-
cellular matrix proteins and intercellular contact pro-
teins [2]. Various ADAMs are expressed in bronchial
epithelium of the human lung [3]. Moreover, elevated
MMP-2, -9, -12 and -14 levels have been reported in
COPD before and/or during exacerbations and in
mouse models [4-11]. Therefore, metalloproteinases may
be considered as potential drug targets for the treatment
of COPD.
Interestingly, cigarette smoke has been shown to
reduce the expression of endogenous tissue inhibitors of
metalloproteinase (TIMP)s and to activate ADAM17,
which results in TGF-a shedding in the airway epithelial
cell line NCI-H292 [12-15].
This may have important implications for COPD.
TGF-a is a well-known ligand of the EGF receptor
(EGFR), which was shown to be involved in ADAM17-
dependent mucus hypersecretion and IL-8 production
[12-16]. IL-8 is a chemoattractant for neutrophils [17],
which play a central role in the pathogenesis of COPD
[18]. Indeed, current and ex-smoking COPD patients
display higher IL-8 levels in bronchial epithelium than
healthy smokers [19,20].
Despite emerging implications for ADAMs and MMPs
in COPD, little is known about their regulation, specific
actions in airway epithelium and role in COPD patho-
genesis. We hypothesized that aberrant metalloprotei-
nase activity, in particular activity of the well-known
TGF-a sheddase ADAM17, contributes to increased
epithelial pro-inflammatory responses to cigarette smoke
in COPD. We studied the expression of specific TIMPs
and used pharmacologic inhibitors to study the involve-
ment of ADAMs and MMPs in the release of cytokines
that are relevant to COPD, e.g. TGF-a and IL-8. We did
so in the presence and absence of cigarette smoke
extract (CSE) and compared primary bronchial epithelial
cells (PBECs) from COPD patients and epithelium from
smoking and non-smoking healthy subjects. Our results
demonstrate that IL-8 secretion is regulated indepen-
dently from ADAM17 activity and TGF-a shedding and
that particularly the early release of IL-8 is higher in
COPD than healthy smokers. Our data further suggest
that reduced TIMP-2 levels may contribute to these
differences.
Methods
Epithelial cell culture
PBECs were obtained from 8 severe COPD patients with
GOLD stages III and IV [21] (inclusion based on ≥10
pack-years of smoking, FEV1 <50% of predicted, FEV1/
FVC<70%, median age 56, range 54-65 years, see table I
for patient characteristics) from bronchial brushings by
bronchoscopy using a fiberoptic bronchoscope according
to standard guidelines [22]. Furthermore, we used bron-
chial epithelial cell cultures from 9 healthy smoking
donors (age 48 (39-60) years) as well as 8 healthy non-
smokers (age 54 (43-76) years). These cultures were
derived from 7 smoking and 5 non-smoking individuals
from Lonza (Walkersville, MD) and from bronchial
brushings in 2 smoking and 3 non-smoking individuals.
TGF-a (2 hrs) and IL-8 (24 hrs) levels were not differ-
ent in epithelial cells derived from bronchial brushings
when compared to cells derived from Lonza (additional
file 1, Figure S1). The Medical Ethics Committee of our
center approved the study. Signed informed consent was
given by participants. Epithelial cultures of all subjects
were established similarly as described previously [23].
In short, cells were grown in 2.5 ml hormonally-supple-
mented bronchial epithelium growth medium (BEGM,
Lonza), containing 100 U/ml penicillin and 100 μg/ml
streptomycin, in collagen/fibronectin-coated flasks. Cells
were passaged using trypsin and further cultured for
approximately 2-3 weeks until use at passage 2. We
observed that primary epithelial cells from bronchial
brushings grown in BEGM all stain positive for pan-
cytokeratin (clone AE1/AE3; DAKO) after 2 passages
(data not shown). Cells were seeded into 24-well plates
at a density of 1 × 10
5/well, and grown for 3 additional
days. Before experimentation, at 90% confluency, BEGM
was replaced basal medium (BEBM, Lonza) containing
0.5% FCS and cells were rendered quiescent overnight.
Cell viability was evaluated by Trypan Blue staining.
0.5% FCS did not affect cell viability (data not shown).
Preparation of cigarette smoke extract
Cigarette smoke extract (CSE) was prepared as
described previously [24]. In short, Kentucky 2R4F
research-reference cigarettes (The Tobacco Research
Institute, University of Kentucky, Lexington, KY) were
used without filter. Smoke from 2 cigarettes was
bubbled through 25 ml medium (100% CSE). The
extract was prepared freshly, sterilized using a 0.22 μm
filter and used within 30 min.
Chemical reagents and stimulation of the cells
Cells were pretreated for 5 min with broad-spectrum
metalloproteinase inhibitor TAPI-2 (Calbiochem, Omni-
labo International BV, Breda, The Netherlands), the
dual specific ADAM17 and ADAM10 inhibitor
GW280264 or the specific ADAM10 inhibitor GI254023
( b o t hk i n d l yp r o v i d e db yM .J o h n s o n ,G S K ,U K )i na
concentration of 2.5 μM ,b a s e do nt h e i re f f e c t si na
dose-response curve (data not shown), or for 30 min
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Science B.V., Etten-Leur, The Netherlands), specific
EGFR tyrosine kinase inhibitor AG1478 (2 μM, Calbio-
chem) or vehicle (medium/DMSO). Subsequently, cells
were exposed to 0.1, 2.5 or 5% CSE or PMA (5 ng/ml,
Sigma-Aldrich, St. Louis, MO, USA) for 2 hrs (early
release) or 24 hrs (production) and harvested for RNA
isolation or cell lysate preparation. Cell viability was
evaluated by Trypan Blue staining. The used concentra-
tions of CSE did not affect cell viability (data not
shown).
Measurement of IL-8, TGF-a and TIMP secretion levels
Protein levels were measured in cell-free supernatants
using ELISA kits according to the manufacturer’s guide-
lines (R&D systems Europe Ltd., Abingdon, UK).
Realtime RT-PCR
RNA was isolated and cDNA synthesized as described
previously [25]. IL-8 expression was analyzed by real-
time PCR using the Taqman
® according to the manu-
facturer’s guidelines (Applied Biosystems, Foster City,
CA). Validated probes for IL-8 and the house keeping
gene b-actin and the TaqMan Master Mix were pur-
chased from Applied Biosystems.
Immunodetection by western blotting
Total cell lysates were obtained by resuspension of the
cells in 1x sample buffer (containing 2% SDS, 10% gly-
cerol, 2% 2-ME, 60 mM Tris-HCl (pH 6.8) and bromo-
phenol blue) and boiling for 5 min. Expression of
ADAM17 was analyzed by Western blotting using anti-
ADAM17 (R&D systems) and anti-b-actin (Santa Cruz
Biotechnology, Santa Cruz, CA) as loading control as
described [26]. Relative protein levels were quantified
using the gelscan program QuantityOne.
Statistical analysis
Data were analyzed using the non-parametric rank-sum
Mann Whitney U test for analysis between subject
groups and the non-parametric Wilcoxon-signed rank
test for paired observations within subject groups.
Results
We performed studies on TGF-a and IL-8 release in
PBECs from healthy non-smokers, smokers and patients
with COPD.
Regulation of TGF-a shedding
S i n c ew ep r o p o s e da ni m p o r t a n tr o l ef o rA D A M 1 7 -
mediated TGF-a shedding in epithelial IL-8 secretion in
COPD, we first studied the regulation of TGF-a shed-
ding by analyzing its early release at 2 hrs. Baseline
levels of TGF-a were clearly detectable in culture
supernatants of all donor groups. On the other hand,
EGFR/ErbB1 ligands EGF and HB-EGF were not detect-
able at this time point. Unexpectedly, we observed that
TGF-a baseline levels were significantly lower in PBECs
from COPD patients than from non-smokers (p < 0.05,
Figure 1A), while intermediate levels were detected in
smokers. In contrast to the data previously described in
the cell line NCI-H292 [14], CSE (0.1%, 2.5% and 5%)
did not affect TGF-a levels in any of the groups (data
shown for 2.5% in Figure 1B), although 5% CSE signifi-
cantly impacted on trans-epithelial resistance (data not
shown). We used the non-specific metalloproteinase
activator phorbol myristate acetate (PMA) as a positive
control. Unlike CSE, PMA increased TGF-a levels in all
groups to a similar extent (~1.5 fold, Figure 1C). The
PMA-induced TGF-a shedding was completely blocked
by ADAM17/10 inhibitor GW280264 (Figure 1C), but
was not affected by specific ADAM10 inhibitor
GI254023 (additional file 2, Figure S2), indicating that
ADAM17 is the main PMA-induced sheddase of TGF-a
upon PBEC activation. Baseline TGF-a levels were also
significantly reduced by GW280264, with a reduction of
29 ± 3%, 31 ± 2% and 29 ± 2% in non-smokers, healthy
smokers and COPD patients respectively (Figure 1D).
TGF-a levels were reduced to a similar extent by TAPI-
2, i.e. by 31 ± 2%, 30 ± 3% and 32 ± 5% respectively
(Figure 1D). These data indicate that ADAM17 is also
the main sheddase of TGF-a under resting conditions.
Thus, a reduction in ADAM17 expression or activity
could be a plausible explanation for the reduced secre-
tion of TGF-a by COPD epithelium. We analyzed differ-
ences in ADAM17 expression by western blotting in 3-4
donors per group. Surprisingly, ADAM17 expression
was not lower, but even higher in COPD than in the
control groups (Figures 2A, B). Thus, we hypothesized
that differences in ADAM17 membrane localization
and/or ADAM17 activity could contribute to the differ-
ences in TGF-a levels. We tested the secretion of
TIMP-3, a potent endogenous inhibitor of ADAM17
activity. However, TIMP-3 levels were not significantly
different between the groups (Figure 2C). In further
contrast to TGF-a, TIMP-3 levels were significantly
reduced upon 24 hrs of CSE exposure (additional file 3,
Figure S3).
Together, our data indicate that ADAM-17 is impor-
tant in constitutive TGF-a shedding and after PMA-
stimulation, but that alterations in ADAM17 expres-
sion itself or its endogenous inhibitor do not likely
contribute to the differences in TGF-a shedding at 2
hours. This is in agreement with the finding that TGF-
a levels were still significantly reduced in COPD (20
(25-17) pg/ml) compared to the non-smokers (29 (39-
17) pg/ml) group in the presence of GW280264 (p <
0.05).
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Page 3 of 11Figure 1 Basal TGF-a levels are reduced in PBECs from COPD patients versus healthy non-smoking controls, not affected by CSE,
induced by PMA and dependent on ADAM17 in PBECs from non-smokers (n=8 ), healthy smokers (n=9 ) and COPD patients (n=8 ).
Upon overnight growth factor-deprivation, total cell lysates were prepared or cells were pre-treated with and without GW280264 (2.5 μM), TAPI-2
(2.5 μM) or DMSO for 30 min and incubated with medium, CSE (2.5%) or PMA (5 ng/ml) for 2 or 24 hrs (as indicated). A) TGF-a levels are
reduced in PBECs from COPD patients versus non-smokers under basal conditions. Absolute values and medians are shown. Significance is
indicated (* = p < 0.05). B) TGF-a levels are not altered by CSE exposure and TGF-a levels are still reduced in PBECs from COPD patients versus
non-smokers upon CSE exposure. Absolute values are shown. Significance is indicated (* = p < 0.05). C) Increase in TGF-a levels upon PMA
exposure to a similar level in PBECs from the 3 different subject groups, which is inhibited by GW280264. Absolute values are shown.
Significance is indicated (** = p < 0.01). D) GW280264 and TAPI-2 inhibit basal release of TGF-a in the three different subject groups. Absolute
values are shown. Significance is indicated (** = p < 0.01).
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Next, we studied the regulation of IL-8 production. As
described previously [27], a substantial amount of IL-8
was secreted under baseline conditions (0.8-8.7 ng/ml).
In contrast to TGF-a,n os i g n i f i c a n td i f f e r e n c e sw e r e
observed between cells from non-smokers, healthy smo-
kers and COPD patients (Figure 3A). CSE (2.5%)
induced a small, but significant increase in IL-8 secre-
tion in COPD patients and healthy smokers, but not in
non-smokers (Figure 3B). The use of 5% CSE did not
further increase IL-8 levels (additional file 4, Figure S4),
whereas PMA induced a strong increase in IL-8 produc-
tion in all groups (Figure 3C). PMA-induced IL-8 levels
tended to be higher in COPD patients than in healthy
smokers (p = 0.07, Figure 3C).
In contrast to a previous report in NCI-H292 cells
[28], GW280264 did not significantly inhibit basal IL-8
production in PBEC from all donor groups (Figure 3D),
either with or without CSE or PMA (data not shown).
However, the broad-spectrum metalloproteinase inhibi-
tor TAPI-2 exerted a substantial and significant inhibi-
tory effect in all groups both under basal conditions (39
± 7%, 34 ± 11% and 33 ± 9% in non-smokers, healthy
smokers and COPD respectively, Figure 3D) and upon
CSE exposure (additional file 5, Figure S5). Together,
these data suggest that a TAPI-2-sensitive metalloprotei-
nase different from ADAM17 (or ADAM10) is involved
in baseline and smoke-induced IL-8 production. This is
further supported by the observation that the reduction
in TGF-a levels was not accompanied by reduced EGFR
and phospho-EGFR (i.e. activated EGFR) expression in
COPD epithelium, as indicated by western blotting
(additional file 6, Figure S6). Thus, shedding of another
EGFR/ErbB1 ligand could be involved in the activation
of EGFR-downstream signaling and subsequent IL-8
production. Although the well-known EGFR ligand EGF
can be shed by ADAM10 [29], GI254023 did not affect
IL-8 production by PBEC under any of the conditions
(data not shown).
Regulation of early IL-8 release
In addition to (EGFR-mediated) de novo synthesis, we
speculated that IL-8 levels may be regulated by a shed-
ding process. Shedding of surface-immobilized IL-8 has
been reported in complex with syndecan-1 [30], a pro-
teoglycan that is known to form a complex with various
chemokines and that can be cleaved by metalloprotei-
nases [31]. Therefore, we investigated if metalloprotei-
nases contribute to early release of IL-8.
We observed an early basal release of IL-8 (2 hrs),
compatible with shedding of syndecan-immobilized IL-8
[31]. Interestingly, this early release was lower in healthy
smokers than in COPD (Figure 4A) and non-smokers.
Differences in IL-8 mRNA expression (2 hrs) did not
correspond to differences in protein IL-8 levels between
the groups (Figure 4B), as IL-8 mRNA expression was
lower in epithelium from COPD than from healthy smo-
kers and non-smokers. This further supports a role for
increased shedding of surface-immobilized IL-8 in
COPD.
The early release of IL-8 was not significantly altered
by CSE (additional file 7, Figure S7). In contrast, PMA
significantly increased the release of IL-8 at 2 hrs (Fig-
ure 4C), which was substantially inhibited by TAPI-2,
but not by GW280264 or GI254023 (data not shown) in
Figure 2 Differences in baseline TGF-a levels are not related to
differences in ADAM17 expression between groups. PBECs were
cultured and seeded in duplicates. Cultures were growth factor-
deprived overnight and directly harvested for total cell lysates or
incubated for 24 hrs with and without 5% CSE. A) ADAM17 and
actin were detected by western blotting in PBECs from non-smokers
(n=4 ), healthy smokers (n=3 ) and COPD patients (n=4 )a s
indicated by arrows. B) Densitometry was performed and levels
were related to actin levels. The ADAM17/actin ratios and medians
are depicted. Significance is indicated (* = p < 0.05). C) TIMP-3
levels are not different between groups. Absolute values and
medians are shown.
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Page 5 of 11Figure 3 IL-8 production in PBECs is not dramatically affected by CSE, strongly enhanced by PMA and sensitive to broad-spectrum
metalloprotease inhibitor TAPI-2. PBEC were obtained from non-smokers (n=7 ), healthy smokers (n=9 ) and COPD patients (n=8 ). Cells were
growth factor-deprived overnight, pre-treated with and without GW280264 (2.5 μM), TAPI-2 (2.5 μM) or medium/DMSO for 30 min and incubated
with and without CSE (2.5%) or PMA (5 ng/ml) for 24 hours. A) IL-8 production is not significantly different in the 3 different subject groups under
basal conditions. Absolute values and medians are shown. B) CSE induces a slight but significant increase in IL-8 production in the healthy smoker
and COPD group. Absolute values are shown and significance is indicated (* = p < 0.05). C) PMA induces a similar increase in IL-8 production in
PBECs from the 3 different subject groups. Absolute values and medians are shown. D) TAPI-2 reduced IL-8 production in PBEC from the 3 different
subject groups. Significance is indicated. Absolute values are shown. Significance is indicated (* = p < 0.05 and ** = p < 0.01).
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Page 6 of 11Figure 4 Early levels of IL-8 are reduced in PBECs from healthy smokers versus COPD patients, induced by PMA and slightly sensitive
to TAPI-2. Cells were growth factor-deprived overnight, pre-treated with medium TAPI-2 (2.5 μM) for 30 min and incubated with medium, CSE
(2.5%) or PMA (5 ng/ml) for 2 hrs. A) IL-8 levels are significantly reduced in PBECs from smokers versus non-smokers and COPD patients under
basal conditions. Absolute values and medians are shown. Significance is indicated (* = p < 0.05 and ** = p < 0.01). B) IL-8 mRNA expression
was determined by real-time PCR. IL-8 Ct values were subtracted from b-actin Ct values, thus lower ΔCt values reflect lower mRNA levels. ΔCt
levels and medians are shown. Significance is indicated (* = p < 0.05 and ** = p < 0.01). C) PMA increases IL-8 release in PBEC from the 3
different subject groups, which can be inhibited by TAPI-2. Absolute values are shown and significance is indicated (* = p < 0.05 and ** = p <
0.01). D) TAPI-2 significantly inhibits basal IL-8 levels in PBECs from non-smokers and healthy smokers, but not from COPD patients. Absolute
values are shown and significance is indicated (** = p < 0.01).
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In line with this, early IL-8 release was inhibited by
T A P I - 2( b y1 9±8 % ,1 2±5 %a n d1 2±1 3 %i nn o n -
smokers, healthy smokers and COPD patients, respec-
tively, Figure 4D), although this effect was not signifi-
cant for COPD (p = 0.14). Interestingly, it has been
described that TIMP-2 inhibits the actions of MMP-14
(MT1-MMP) [32], a known sheddase of syndecans. We
therefore studied TIMP-2 and did the important obser-
vation that TIMP-2 levels were significantly reduced in
the COPD group versus healthy donors in absence and
presence of CSE (Figures 5A and 5B). Thus, loss of this
type of regulation of metalloproteinase activity in COPD
patients may very well contribute to the increased shed-
ding of immobilized IL-8 in COPD versus healthy smo-
ker epithelium.
Discussion
MMPs and ADAMs may play a pivotal role in airway
remodeling and in pro-inflammatory responses of airway
epithelium, as occurs in COPD. We assessed the invol-
vement of metalloproteinases in the secretion of IL-8
and TGF-a, cytokines of importance to COPD develop-
ment and progression. We investigated the effects of
CSE on these cytokines and the possible differences in
their regulation in bronchial epithelium from COPD
patients, healthy smokers and non-smokers. In striking
contrast to data previously published in a cell line [14],
our data in primary epithelium show that CSE does not
induce ADAM17-dependent TGF-a shedding and only
slightly increases IL-8 production. Interestingly, we
observed an early IL-8 release by PBEC, likely due to
shedding. This early release was higher in PBECs from
COPD patients than from healthy smokers and was
accompanied by reduced levels of endogenous metallo-
proteinase inhibitor TIMP-2. Whereas ADAM17 was
the main sheddase of TGF-a, we show for the first time
that a TAPI-2-sensitive metalloproteinase different from
ADAM17 is involved in the regulation of IL-8 release,
independently from TGF-a shedding.
We demonstrate that TGF-a shedding is strongly
dependent on ADAM17 activity, in contrast to IL-8
secretion. Given the implications for TGF-a in epithelial
mucus secretion [14], ADAM17 could serve as potential
target for new treatment strategies to reduce mucus
hypersecretion in COPD. On the other hand, however,
ADAM17 may not be a promising target for the
attenuation of IL-8-induced neutrophil recruitment.
In contrast to previous observations in NCI-H292 cells
[28], IL-8 secretion was not significantly inhibited by
ADAM17 inhibition. This stresses the fact that studies
in airway epithelial cell lines cannot simply be extrapo-
lated to primary cells and should be interpreted care-
fully. More importantly, our data suggest that another,
yet unidentified TAPI-2-sensitive metalloproteinase is
involved in IL-8 production by airway epithelium. Dif-
ferences in the regulation of this specific metalloprotei-
nase may contribute to the aberrant pro-inflammatory
responses of COPD epithelium. Therefore, it is of inter-
est to identify this metalloproteinase in future studies,
offering potential leads for novel therapeutic strategies
in COPD.
TGF-a and IL-8 levels were also differentially regu-
lated by CSE, the release of TGF-a being unaffected,
while IL-8 production (24 hrs) was slightly increased in
COPD patients and healthy smokers. Previously, Kode et
al have shown a stronger CSE-induced increase of IL-8
in primary epithelium [33]. The dissimilarity between
the studies may be attributed to differences in smoke
extract preparation and to the fact that Kode et al used
small airway epithelial cells from only a single healthy
non-smoker. We observed that the modest upregulatory
effect of CSE on IL-8 levels was accompanied by a sig-
nificant reduction in TIMP-3 levels upon CSE exposure.
Besides ADAM17, TIMP-3 can affect several sheddases,
including MMP-9, MMP-14 (MT1-MMP), well-known
sheddases of EGFR ligands [34,35]. We speculate that
these TIMP-3-sensitive sheddases may thus be involved
in the upregulatory effect of CSE on IL-8 production.
With respect to differential epithelial responses in
non-smokers, healthy smokers and COPD patients,
shedding of TGF-a (both baseline and in presence of
CSE) was lower in PBEC from COPD patients than
from healthy non-smokers, with intermediate levels in
healthy smokers. Our data do not support a role for a
reduction in functional ADAM17 in the decreased TGF-
a shedding in COPD patients. Thus, reduced de novo
synthesis, trafficking or surface expression of TGF-a are
presumably involved. Since TGF-a has been implicated
in epithelial repair, the increased expression of
ADAM17 observed on COPD epithelium may be an
Figure 5 TIMP-2 levels are reduced in PBEC from COPD
patients versus PBECs from the control groups. Cells were
growth factor-deprived overnight and incubated for 24 hrs in A)
absence and B) presence of CSE (2.5%). Absolute values and
medians are shown. Significance is indicated (* = p < 0.05).
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eration in a situation of chronic damage.
We found similar baseline and CSE-induced IL-8 pro-
duction (24 hrs) in all PBEC groups. In contrast to our
findings, Schneider et al demonstrated increased base-
line epithelial IL-8 production in COPD patients [36].
The discrepancy between the studies may be due the
different culture procedures, as Schneider et al cultured
their cells at air-liquid interface. It will be thus of inter-
est to study epithelial IL-8 production upon submerged
as well as air-liquid interface culture and to expand our
subject groups to COPD patients and control groups
matched for current and ex smoking in a future study.
Although inflammatory responses in COPD are thought
to persist for years after smoking cessation, a limitation
in our current study is the fact that only ex-smoking
COPD patients were included. Nevertheless, Schulz et al
[37] were also not able to detect differences in baseline
IL-8 production in submerged cultured PBEC from cur-
rently smoking COPD patients and smoking controls.
Intriguingly, our data suggest that instead of its pro-
duction, the shedding of immobilized IL-8 be may be
altered in COPD patients versus healthy smokers. The
early release of IL-8 was significantly higher in COPD
than healthy smokers, and IL-8 mRNA expression did
not correspond to this differential IL-8 release. On the
contrary, differences in IL-8 mRNA expression did
relate to differences in TGF-a levels between groups.
Thus, it is possible that the early release of IL-8
obscures potential TGF-a-mediated effects on its tran-
scriptional regulation in PBECs. The early IL-8 release
was not affected by ADAM17/10 inhibitor GW280264,
but slightly inhibited by TAPI-2. Differences between
groups were still observed in the presence of TAPI-2,
indicating that TAPI-2-insensitive metalloproteinases
could also contribute to this early release. Based on our
findings and literature data [30], we suggest that this
may be due to differential shedding of syndecan-bound
IL-8. TAPI-2-insensitive MMP-14 has been identified as
sheddase of syndecan-1, and this effect was inhibited by
TIMP-2 expression [31,32]. Decreased expression of
TIMP-2 mRNA has previously been reported in COPD
versus control lung tissue [38] along with increased
MMP-14 levels and/or activity in COPD patients [8].
We observed that TIMP-2 levels were significantly
lower in PBECs from COPD than from healthy non-
smokers and smokers. Thus, lower TIMP-2 levels may
be specific for disease and not related to long-term
smoking.
Together, our data suggest that reduced TIMP-2 levels
in COPD may lead to altered epithelial MMP activity
and shedding of syndecan-bound chemokines (e.g. IL-8).
It will therefore be of interest to study TIMP-2 levels in
sputum or BAL fluid from COPD patients in future
studies and test whether these are related to changes in
MMP-14 activity, IL-8 levels and neutrophilia. Further-
more, our data suggest that cigarette smoke does not
directly alter the activity of ADAMs and MMPs in air-
way epithelium, but it may indirectly regulate their
activity through their endogenous inhibitors, i.e. TIMP-3
(but not TIMP-2).
Conclusions
Our data indicate that IL-8 secretion is regulated inde-
pendently from ADAM17 activity and TGF-a shedding
and that particularly its early release is differentially
regulated in PBECs from COPD and healthy smokers.
Our data further suggest that reduced TIMP-2 levels
may contribute to the increased shedding of IL-8 in
COPD, leading to increased activity of metalloprotei-
nases sensitive to TIMP-2, e.g. MMP-9 and -14. These
metalloproteinases may thus be potential targets for
novel therapeutic strategies to reduce airway inflamma-
tion in COPD.
Additional material
Additional file 1: Baseline TGF-a and IL-8 levels are not significantly
different between epithelial cells (healthy smokers and non-
smokers) obtained by bronchial brushings (brush) and normal
human bronchial epithelium (NHBE) derived from Lonza. PBEC were
growth factor-deprived overnight, pre-treated and incubated with
medium. A) TGF-a levels at 2 hrs. Absolute values and medians are
shown. B) IL-8 levels at 24 hrs. Absolute values and medians are shown.
Additional file 2: TGF-a shedding in PBECs from COPD patients.
PBECs were growth factor-deprived overnight and treated with and
without GI254023 (2.5 μM) or GW280264 (2.5 μM) for 2 hrs. Absolute
TGF-a levels and medians are shown.
Additional file 3: TIMP-3 levels are significantly reduced by CSE
exposure in PBECs from smokers and COPD, but not from healthy
controls. PBECs were cultured and seeded in duplicates. Cultures were
growth factor-deprived overnight and directly harvested for total cell
lysates or incubated for 24 hrs with and without 5% CSE. Absolute values
are shown. Significance is indicated (* = p < 0.05 and p**=<0.01).
Additional file 4: IL-8 secretion in PBECs is not significantly
different upon exposure to 5% CSE compared to 2.5% CSE. PBEC
from non-smokers (circles), healthy smokers (squares) and COPD patients
(triangles) were growth factor-deprived overnight and incubated with
medium or CSE (2.5% and 5%) for 24 hrs. Exposure to 5% CSE does not
further increase IL-8 levels in PBECs from smokers/COPD patients nor
induce an increase in PBECs from non-smokers. Absolute values are
shown.
Additional file 5: CSE-induced IL-8 secretion in PBECs is significantly
inhibited by TAPI-2. PBEC from non-smokers, healthy smokers and
COPD patients were growth factor-deprived overnight, pre-treated with
and without TAPI-2 (2.5 μM) and incubated with medium or 2.5% CSE
for 24 hrs. TAPI-2 significantly inhibits CSE-induced IL-8 levels in PBEC.
Absolute values are shown. Significance is indicated (* = p < 0.05 and **
= p < 0.01).
Additional file 6: Basal phospho-EGFR levels are not different
between the subject groups. PBECs from non-smokers (n=4 ), healthy
smokers (n=4 ) and COPD patients (n=4 ) were growth-factor deprived
overnight and total cell lysates were prepared. EGFR and phospho-EGFR
detected by western blotting using anti-phospho-EGFR (1173 tyrosine
residue) and anti-EGFR (Santa Cruz Biotechnology, Santa Cruz, CA).
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EGFR. Ratios and medians are depicted.
Additional file 7: Early levels of IL-8 are not induced by CSE in
PBECs. Cells were growth factor-deprived overnight and incubated with
medium or 2.5% CSE for 2 hrs. CSE has no effect on IL-8 levels in PBEC
from the 3 different subject groups. Absolute values are shown.
Abbreviations
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heparan sulfate proteoglycans; MMP: Matrix metalloproteinase; PBECs:
primary bronchial epithelial cells; PMA: phorbol myristate acetate; ROS:
reactive oxygen species; TIMP: tissue inhibitor of metalloproteinase.
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